← Back to Search

Diagnostic Imaging with 64Cu-PSMA-I&T for Prostate Cancer

Phase 2

Waitlist Available

Research Sponsored by Curium US LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 hours

Awards & highlights

Study Summary

This trial evaluates a new imaging technique to detect recurrent prostate cancer after treatment.

Eligible Conditions

Prostate Cancer Metastasis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Adverse Events

Patient-Level Correct Detection Rate (CDR)

Region-Level Correct Localization Rate (CLR)

Secondary outcome measures

Score of Image Quality

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic Imaging with 64Cu-PSMA-I&TExperimental Treatment1 Intervention

64Cu-PSMA I&T

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

64Cu-PSMA I&T

2022

Completed Phase 2

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Curium US LLCLead Sponsor

4 Previous Clinical Trials

962 Total Patients Enrolled

2 Trials studying Prostate Cancer

523 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How widespread is the availability of this medical experiment?

"This clinical study has 5 participating sites, including Saint Louis University in Missouri and Washington University in Omaha. Furthermore, Nebraska Cancer Specialists is offering patient support in Houston, with additional locations available as well."

Answered by AI

How perilous is 64Cu-PSMA-I&T for patient health when utilized in Diagnostic Imaging?

"Our Power team assesses the safety of Diagnostic Imaging with 64Cu-PSMA-I&T to be a 2 because, although Phase 2 indicates some evidence for safety, there is yet to be any proof of its efficacy."

Answered by AI

Is there still room for participants in this research project?

"As reported on clinicaltrials.gov, the recruitment process for this particular trial has concluded. Initially posted December 1st 2022 and last updated December 7th 2022, it is no longer accepting any participants at this time; however, there are an abundance of other studies available now numbering 3601 in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

2022. "Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05653856.